HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer

47OPhase 1 study of bispecific HER2 antibody-drug conjugate MEDI4276 in patients with advanced HER2-positive breast or gastric cancer

(2018) M Pegram et al.   ANNALS OF ONCOLOGY

Abstract GS1-02: NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC)

(2018) L Fehrenbacher et al.   CANCER RESEARCH

Treatment of advanced HER2-positive breast cancer: 2018 and beyond

(2018) Noam Pondé et al.   CANCER TREATMENT REVIEWS

Structural insights into the mechanism of action of a biparatopic anti-HER2 antibody

(2018) Vaheh Oganesyan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

(2018) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes

(2018) Valeriy Domenyuk et al.   Nature Communications

Abstract LB-294: Synergy of an anti-HER2 ADC TAK-522 (XMT-1522) in combination with anti-PD1 monoclonal antibody (mAb) in a syngeneic breast cancer model expressing human HER2

(2018) Tary Traore et al.   CANCER RESEARCH

Safety, pharmacokinetics and efficacy of RC48-ADC in a phase I study in patients with HER2-overexpression advanced solid cancer.

(2018) Jifang Gong et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer.

(2018) Cristina Saura et al.   JOURNAL OF CLINICAL ONCOLOGY

An open-label, dose-escalation phase I study to evaluate RC48-ADC, a novel antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.

(2018) Jiayu Wang et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients (pts) with HER2-expressing breast, lung and gastric tumors.

(2018) Erika Paige Hamilton et al.   JOURNAL OF CLINICAL ONCOLOGY

An open-label, multicenter, phase Ib study to evaluate RC48-ADC in patients with HER2-positive metastatic breast cancer.

(2018) Binghe Xu et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts.

(2018) Hiroji Iwata et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

(2018) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Strategies and challenges for the next generation of antibody–drug conjugates

(2017) Alain Beck et al.   NATURE REVIEWS DRUG DISCOVERY

Antibody-drug conjugates—an emerging class of cancer treatment

(2016) Nikolaos Diamantis et al.   BRITISH JOURNAL OF CANCER

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy

(2016) John Y. Li et al.   CANCER CELL

Abstract P4-14-28: XMT-1522 induces tumor regressions in pre-clinical models representing HER2-positive and HER2 low-expressing breast cancer

(2016) DA Bergstrom et al.   CANCER RESEARCH

Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity

(2016) Yusuke Ogitani et al.   CANCER SCIENCE

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

(2016) Y. Ogitani et al.   CLINICAL CANCER RESEARCH

A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity

(2015) Xuejing Yao et al.   BREAST CANCER RESEARCH AND TREATMENT

HER2 expression status in diverse cancers: review of results from 37,992 patients

(2015) Min Yan et al.   CANCER AND METASTASIS REVIEWS

Abstract 639: Site specific conjugation of ARX-788, an antibody drug conjugate (ADC) targeting HER2, generates a potent and stable targeted therapeutic for multiple cancers

(2015) Robin C. Humphreys et al.   CANCER RESEARCH

Abstract LB-231: A novel, highly potent HER2-targeted antibody-drug conjugate (ADC) for the treatment of low HER2-expressing tumors and combination with trastuzumab-based regimens in HER2-driven tumors

(2015) Donald A. Bergstrom et al.   CANCER RESEARCH

Abstract 641: Trastuzumab-dolaflexin, a highly potent Fleximer-based antibody-drug conjugate, demonstrates a favorable therapeutic index in exploratory toxicology studies in multiple species

(2015) Natalya Bodyak et al.   CANCER RESEARCH

The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers

(2015) M. M. C. van der Lee et al.   MOLECULAR CANCER THERAPEUTICS

Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985

(2015) Ronald C. Elgersma et al.   MOLECULAR PHARMACEUTICS

Tissue-based map of the human proteome

(2015) M. Uhlen et al.   SCIENCE

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

(2014) Ian E Krop et al.   LANCET ONCOLOGY

Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform

(2014) W. Dokter et al.   MOLECULAR CANCER THERAPEUTICS

A Retrospective Population-Based Comparison of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization in Breast Carcinomas: Impact of 2007 American Society of Clinical Oncology/ College of American Pathologists Criteria

(2013) Kurt A. Schalper et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

HER2and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial

(2010) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate

(2008) G. D. Lewis Phillips et al.   CANCER RESEARCH